Publication Name	World Journal of Translational Medicine
Manuscript ID	12821
Country	Italy

Received	2014-07-27 16:41
Peer-Review Started	2014-07-27 23:24
To Make the First Decision	2014-09-16 10:59
Return for Revision	2014-09-16 17:13
Revised	2014-09-25 22:34
Second Decision	2014-11-03 16:59
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-11-03 17:11
Articles in Press	2014-11-03 17:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-25 11:16
Publish the Manuscript Online	2014-12-13 17:57

ISSN	2220-6132 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Minireviews
Article Title	Pharmacogenetics of type 2 diabetes mellitus: An example of success in clinical and translational medicine
Manuscript Source	Invited Manuscript
All Author List	Antonio Brunetti, Francesco S Brunetti and Eusebio Chiefari
Funding Agency and Grant Number
Corresponding Author	Antonio Brunetti, Professor, Department of Health Sciences, University “Magna Græcia” of Catanzaro, V.le Europa (Loc. Germaneto), 88100 Catanzaro, Italy. brunetti@unicz.it
Key Words	Type 2 diabetes; Anti-diabetic drugs; Personalized therapy; Genetic variants; Genome-wide association study
Core Tip	Type 2 diabetes mellitus (T2DM) is a heterogeneous complex disorder, in which predisposing genetic variants (polymorphisms) and precipitating environmental factors interact synergistically in the development of the disease. Besides being useful in identifying individuals at risk for T2DM, knowledge of the polymorphisms associated with T2DM is also useful in pharmacogenetics for correlating individual variants with individual responses to anti-diabetic drugs. To date, a wide variety of genes that influence pharmacogenetics of anti-diabetic drugs have been identified. However, with few exceptions, drug therapy has not taken into account the individual genetic diversity of treated patients, representing, this, a substantial limitation of pharmacogenetics. This review focuses on clinically important polymorphisms affecting a patient’s response to diabetic medications.
Publish Date	2014-12-13 17:57
Citation	Brunetti A, Brunetti FS, Chiefari E. Pharmacogenetics of type 2 diabetes mellitus: An example of success in clinical and translational medicine. World J Transl Med 2014; 3(3): 141-149
URL	http://www.wjgnet.com/2220-6132/full/v3/i3/141.htm
DOI	http://dx.doi.org/10.5528/wjtm.v3.i3.141

Full Article (PDF)	WJTM-3-141.pdf
Full Article (Word)	WJTM-3-141.doc
Manuscript File	12821-Review.docx
Answering Reviewers	12821-Answering reviewers.pdf
Copyright License Agreement	12821-Copyright assignment.pdf
Peer-review Report	12821-Peer review(s).pdf
Scientific Misconduct Check	12821-CrossCheck.jpg
Scientific Editor Work List	12821-Scientific editor work list.pdf